Nothing Special   »   [go: up one dir, main page]

EA200300663A1 - Антагонисты cxcr3 - Google Patents

Антагонисты cxcr3

Info

Publication number
EA200300663A1
EA200300663A1 EA200300663A EA200300663A EA200300663A1 EA 200300663 A1 EA200300663 A1 EA 200300663A1 EA 200300663 A EA200300663 A EA 200300663A EA 200300663 A EA200300663 A EA 200300663A EA 200300663 A1 EA200300663 A1 EA 200300663A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammatory
diseases
applicable
treatment
compounds
Prior art date
Application number
EA200300663A
Other languages
English (en)
Other versions
EA007538B1 (ru
Inventor
Джулио К. Медина
Майкл Дж. Джонсон
Ан-Ронг Ли
Дживен Лиу
Алан Кси Хуанг
Лиушенг Жу
Эндрю П. Маркус
Original Assignee
Туларик Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Туларик Инк. filed Critical Туларик Инк.
Publication of EA200300663A1 publication Critical patent/EA200300663A1/ru
Publication of EA007538B1 publication Critical patent/EA007538B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложены соединения, композиции и способы, которые применимы при лечении воспалительных и иммунных состояний и заболеваний. В частности, изобретение относится к соединениям, которые модулируют экспрессию и/или функцию рецептора хемокина. Предложенные способы применимы для лечения воспалительных и иммунорегуляторных расстройств и заболеваний, таких как рассеянный склероз, ревматоидный артрит и диабет типа I.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300663A 2000-12-11 2001-12-11 Антагонисты cxcr3 EA007538B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25524100P 2000-12-11 2000-12-11
US29649901P 2001-06-06 2001-06-06
PCT/US2001/047850 WO2002083143A1 (en) 2000-12-11 2001-12-11 Cxcr3 antagonists

Publications (2)

Publication Number Publication Date
EA200300663A1 true EA200300663A1 (ru) 2004-06-24
EA007538B1 EA007538B1 (ru) 2006-10-27

Family

ID=26944548

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300663A EA007538B1 (ru) 2000-12-11 2001-12-11 Антагонисты cxcr3

Country Status (19)

Country Link
US (3) US6964967B2 (ru)
EP (1) EP1343505A1 (ru)
JP (1) JP4259877B2 (ru)
KR (1) KR100883184B1 (ru)
CN (1) CN1575177A (ru)
AU (1) AU2001297717B2 (ru)
BR (1) BR0116096A (ru)
CA (1) CA2431553A1 (ru)
CZ (1) CZ20031910A3 (ru)
EA (1) EA007538B1 (ru)
HU (1) HUP0500880A2 (ru)
IL (2) IL156304A0 (ru)
MX (1) MXPA03005152A (ru)
NO (1) NO325450B1 (ru)
NZ (1) NZ526622A (ru)
PL (1) PL366311A1 (ru)
SK (1) SK8752003A3 (ru)
WO (1) WO2002083143A1 (ru)
ZA (1) ZA200304342B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2617989C2 (ru) * 2006-09-26 2017-05-02 Селджин Корпорейшн Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60010448T2 (de) 1999-03-17 2005-04-07 Astrazeneca Ab Amid-derivate
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
EP1343505A1 (en) * 2000-12-11 2003-09-17 Tularik Inc. Cxcr3 antagonists
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ES2623982T3 (es) 2001-12-21 2017-07-12 Genzyme Corporation Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7009049B2 (en) 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
AU2003228283A1 (en) 2002-03-07 2003-09-22 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
US6900219B2 (en) 2002-04-04 2005-05-31 Cv Therapeutics, Inc. ABCA-1 elevating compounds
NZ536190A (en) * 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
EP1553931A4 (en) 2002-05-09 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
CA2485148A1 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
US7244555B2 (en) * 2002-05-14 2007-07-17 Renovak Inc Systems and methods for identifying organ transplant risk
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2006506401A (ja) * 2002-05-23 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
WO2003106426A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
EP1539727B1 (en) * 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2003267169A1 (en) * 2002-09-13 2004-04-30 Cytokinetics, Inc. Compounds, compositions and methods
EP1558083A4 (en) 2002-09-30 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
DE10301650A1 (de) * 2003-01-17 2004-07-29 Johannes-Gutenberg-Universität Mainz Medizinisch nützliche 1-Phenyl-2-aminomethylnaphthaline, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
US20040242498A1 (en) * 2003-02-27 2004-12-02 Collins Tassie L. CXCR3 antagonists
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
SE0300627D0 (sv) * 2003-03-07 2003-03-07 Astrazeneca Ab Novel fused heterocycles and uses therof
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
US7399776B2 (en) 2003-04-02 2008-07-15 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
AU2004229404B2 (en) * 2003-04-11 2008-01-10 Taigen Biotechnology Aminoquinoline compounds
US7378524B2 (en) 2003-04-11 2008-05-27 Taigen Biotechnology Co., Ltd. Aminoquinoline compounds
US7741341B2 (en) * 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
MXPA05013142A (es) 2003-06-20 2006-03-17 Chiron Corp Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
JP2007523858A (ja) * 2003-06-24 2007-08-23 ユニバーシティ オブ コネチカット 血管透過性およびアポトーシスの阻害方法
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1506967B1 (en) * 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
WO2005021537A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
JP2006193426A (ja) * 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
EP1670456A2 (en) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Compounds, compositions and methods
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
EP1682534A2 (en) * 2003-11-03 2006-07-26 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions, and methods
WO2005046588A2 (en) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005061460A1 (en) 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
EP1722787A4 (en) * 2004-03-08 2007-09-26 Wyeth Corp ION CHANNEL MODULATORS
US20090208486A1 (en) * 2004-03-09 2009-08-20 Makoto Taketo Pharmaceutical composition comprising cxcr3 inhibitor
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
UA85871C2 (ru) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Ингибиторы дипептидилпептидазы
PL1753723T3 (pl) 2004-05-21 2009-01-30 Novartis Vaccines & Diagnostics Inc Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych
EP1753730A1 (en) 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US7271271B2 (en) * 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7375102B2 (en) * 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2008509977A (ja) 2004-08-18 2008-04-03 アストラゼネカ アクチボラグ 癌の処置及び予防における選択された縮合複素環の鏡像異性体及びその使用
EP1786265A4 (en) * 2004-08-30 2009-08-19 Smithkline Beecham Corp NEW COMPOSITIONS AND PROCESSING METHODS
PE20060598A1 (es) 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
EP1811844A4 (en) * 2004-09-14 2009-12-02 Minerva Biotechnologies Corp METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
JP4698991B2 (ja) * 2004-09-14 2011-06-08 日本曹達株式会社 ピリジルメチルカルバミン酸エステル化合物、その製造方法及びピリジルメチルアミン化合物の製造方法
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
JP2008521903A (ja) 2004-12-01 2008-06-26 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｎ置換されたベンズイミダゾリルＣ−ｋｉｔ阻害剤及びコンビナトリアルベンゾイミダゾールライブラリー
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
KR20080009048A (ko) 2005-01-25 2008-01-24 프롤렉시스 파마슈티칼스, 인크. 항종양제로서 퀴녹살린 유도체
CA2598459A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
AU2006214378A1 (en) * 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
TW200714610A (en) * 2005-02-16 2007-04-16 Univ Maryland CXCR3 is a gliadin receptor
KR20070107040A (ko) * 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 갖는 헤테로아릴-치환된피라지닐-피페라진-피페리딘
EP1856098B1 (en) * 2005-02-16 2012-08-01 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
RU2007134259A (ru) * 2005-02-16 2009-03-27 Шеринг Корпорейшн (US) Гетероциклические замещенные пиперазины, обладающие антагонистическим действием к cxcr3
US7763616B2 (en) * 2005-02-16 2010-07-27 Schering Corporation Piperazine-piperidines with CXCR3 antagonist activity
EP1889622A4 (en) 2005-05-31 2009-12-23 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
DE602006015658D1 (de) 2005-06-27 2010-09-02 Amgen Inc Entzündungshemmende arylnitrilverbindungen
WO2007002742A1 (en) * 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
DK1942898T4 (da) 2005-09-14 2014-06-02 Takeda Pharmaceutical Dipeptidylpeptidase-inhibitorer til behandling af diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
AU2006330883A1 (en) * 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc. 3-aryl-substituted quinazolones, and uses thereof
BRPI0708731A2 (pt) 2006-03-10 2011-06-07 Ono Pharmaceutical Co derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo
BRPI0709035A2 (pt) * 2006-03-21 2011-06-21 Schering Corp compostos de piridina substituìda heterocìclica com atividade antagonista de cxcr3
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2551270B1 (en) 2006-04-04 2019-06-12 The Regents of The University of California Pyrazolopyrimidine derivatives for use as pi3 kinase antagonists
AR061975A1 (es) * 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
US7820689B2 (en) * 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
AR062760A1 (es) * 2006-09-13 2008-12-03 Takeda Pharmaceutical Administracion de inhibidores de dipeptidilpetidasa
CN101547922B (zh) 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
US20100216820A1 (en) * 2006-11-13 2010-08-26 White Stephen L Thienopyrimidiones for treatment of inflammatory disorders and cancers
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
KR20090097210A (ko) 2007-01-05 2009-09-15 노파르티스 아게 키네신 방추체 단백질 (ｅｇ－５) 억제제로서의 이미다졸 유도체
CA2677163A1 (en) * 2007-02-01 2008-08-07 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against cxcr3
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8367052B2 (en) 2007-03-26 2013-02-05 General Regeneratives Holdings Inc. Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
CA2695365A1 (en) * 2007-08-03 2009-02-12 Schering Corporation Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2009064802A2 (en) * 2007-11-13 2009-05-22 Eli Lilly & Co. Inhibitors of human phosphatidyl-inositol 3-kinase delta
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN101965336B (zh) 2008-01-04 2015-06-17 英特利凯恩有限责任公司 某些化学实体、组合物和方法
US20110034487A1 (en) * 2008-01-22 2011-02-10 Amgen Inc. Cxcr3 antagonists
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
NZ590258A (en) 2008-07-08 2013-10-25 Intellikine Llc Kinase inhibitors and methods of use
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
JP5819195B2 (ja) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP2013504604A (ja) * 2009-09-18 2013-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤としてのキナゾリノン誘導体
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
PH12013501465A1 (en) 2011-01-10 2013-09-09 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
CA2836311A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
ES2801901T3 (es) * 2011-06-13 2021-01-14 Tla Targeted Immunotherapies Ab Tratamiento de afecciones asociadas al síndrome metabólico
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2015519368A (ja) 2012-06-01 2015-07-09 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ類似体
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013323426A1 (en) 2012-09-26 2015-04-23 The Regents Of The University Of California Modulation of ire1
IL291945A (en) 2012-11-01 2022-06-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US10449210B2 (en) * 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
AU2015231413B2 (en) 2014-03-19 2020-04-23 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US10118900B2 (en) 2015-08-25 2018-11-06 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as CB-1 inverse agonists
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN110402097A (zh) 2016-12-07 2019-11-01 普罗根尼蒂公司 胃肠道检测方法、装置和系统
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CN108794496B (zh) * 2018-04-28 2020-04-24 北京施安泰医药技术开发有限公司 一类cdk抑制剂、其药物组合物、制备方法及用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3876942A1 (en) * 2018-11-05 2021-09-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2024516278A (ja) 2021-05-06 2024-04-12 バイエル・アクチエンゲゼルシヤフト アルキルアミド置換環付加イミダゾール類及び殺虫剤としてのそれらの使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
US5202322A (en) 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
ATE258437T1 (de) 1995-08-02 2004-02-15 Darwin Discovery Ltd Chinolone und deren therapeutische verwendung
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
DE69733825T2 (de) 1996-09-25 2006-06-08 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
EP0946095A1 (en) 1996-12-17 1999-10-06 E.I. Du Pont De Nemours And Company Fungicidal quinazolinones
FR2778662B1 (fr) 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2001016114A2 (en) * 1999-08-27 2001-03-08 Chemocentryx, Inc. Heterocyclic compounds and methods for modulating cxcr3 function
JP4994552B2 (ja) * 1999-09-16 2012-08-08 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路のメディエーター、組成物及びそれらと関連する利用
WO2001030768A1 (en) 1999-10-27 2001-05-03 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ATE372337T1 (de) 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
WO2002028831A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1343505A1 (en) * 2000-12-11 2003-09-17 Tularik Inc. Cxcr3 antagonists
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
MXPA05013142A (es) * 2003-06-20 2006-03-17 Chiron Corp Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2617989C2 (ru) * 2006-09-26 2017-05-02 Селджин Корпорейшн Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения

Also Published As

Publication number Publication date
EA007538B1 (ru) 2006-10-27
US20030055054A1 (en) 2003-03-20
NO20032612D0 (no) 2003-06-10
WO2002083143A1 (en) 2002-10-24
JP2004536796A (ja) 2004-12-09
JP4259877B2 (ja) 2009-04-30
HUP0500880A2 (en) 2006-05-29
KR20030080212A (ko) 2003-10-11
PL366311A1 (en) 2005-01-24
MXPA03005152A (es) 2004-10-14
EP1343505A1 (en) 2003-09-17
SK8752003A3 (en) 2003-11-04
NO20032612L (no) 2003-08-05
NZ526622A (en) 2006-07-28
US20060116388A1 (en) 2006-06-01
IL156304A (en) 2009-02-11
CZ20031910A3 (cs) 2003-12-17
ZA200304342B (en) 2005-08-31
NO325450B1 (no) 2008-05-05
AU2001297717B2 (en) 2006-02-23
BR0116096A (pt) 2005-10-18
US20020169159A1 (en) 2002-11-14
KR100883184B1 (ko) 2009-02-12
CN1575177A (zh) 2005-02-02
US6964967B2 (en) 2005-11-15
IL156304A0 (en) 2004-01-04
CA2431553A1 (en) 2002-10-24
US7053215B2 (en) 2006-05-30

Similar Documents

Publication Publication Date Title
EA200300663A1 (ru) Антагонисты cxcr3
HK1029595A1 (en) Cyclic antagonists of c5a receptors and g protein-coupled receptors
MX2007000051A (es) Derivados de pirimidina fusionados y composiciones de los mismos como moduladores del receptor cxcr3, utiles en la prevencion y tratamiento de trastornos y enfermedades inflamatorias e inmunoregulatorias.
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
DE69633617D1 (de) Il-17 receptor
MY118176A (en) Heterocycles as inhibitors of leucocyte adhesion and as vla-4-antagonists
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
ES2190503T3 (es) Heterociclos de 5 anillos en calidad de inhibidores de la adhesion de leucocitos y antagonistas de vla-4.
MY123865A (en) Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists
MY193350A (en) Anti-vegf protein compositions and methods for producing the same
ECSP066710A (es) Mutantes de anticuerpo anti-cd40
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
DK1534286T3 (da) Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
EA200001041A1 (ru) Антитела к cd23, их производные и их терапевтическое применение
BR9907743A (pt) Anticorpos contra a il-12 humana
IS5543A (is) Nýr G próteintengdur viðtaki
WO2007062175A3 (en) Spiro-substituted tricyclic heterocycles cxcr3 antagonists
EA200201119A1 (ru) Лиганды меланокортиновых рецепторов
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EP1423137A4 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
WO2004075863A3 (en) Cxcr3 antagonists
EA200200933A1 (ru) Антагонисты рецептора il-8

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU